Skye Bioscience, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Skye Bioscience is seeking stockholder approval to triple its authorized common stock to 300 million shares and ratify its board and auditors.
NASDAQ
DEFA14A: Skye Bioscience, Inc. Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
Skye Bioscience, Inc. announces its 2025 Annual Meeting of Stockholders to be held on June 6, 2025, outlining key proposals for voting, including the election of directors and ratification of the company's independent auditor.
NASDAQ
Skye Bioscience is seeking stockholder approval on key governance matters, including the election of directors, ratification of the auditor, and executive compensation, as it advances its CB1-targeted obesity therapeutic program.
NASDAQ
Skye Bioscience is asking stockholders to approve an amended equity incentive plan to increase the number of shares available for issuance and extend the plan's expiration date.